CanTreatCOVID

Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings

Adaptive Platform Trial Scientific Meeting

September 28 – 29, 2023

2nd Floor, Giovanni Room

Chestnut Conference Centre

Toronto, ON, Canada

Conference Objectives

1. Understand the concept and advantages of adaptive platform trials over traditional randomized controlled trials
2. Understand the statistical methods used in adaptive platform trials, including Bayesian methods and sequential hypothesis testing
3. Identify the practical challenges associated with adaptive platform trials and learn how to address them

Join the conversation!

#APTInstitute2023

DAY 1: SEPTEMBER 28

Time	Topic	Speaker(s)
9:00 - 9:15	Welcome & introduction	Drs. Andrew Pinto & Benita Hosseini
09:15 - 10:00	Introduction to adaptive platform trials and their advantages over traditional randomized controlled trials	Dr. Angela Cheung
10:00 - 12:00	Case studies (3) of adaptive platform trials with complex designs, such as trials with multiple arms or multiple stages in different disease areas	Drs. John Marshall, Jamie Forrest, Rubeshan Perumal
12:00 - 13:00	**Photo and lunch break**	
13:00 - 13:45	Bayesian analysis in adaptive trials: sample size calculation, simulation, and sequential hypothesis testing	Dr. Anna Heath
13:45 - 14:30	Hands-on practice session for statistical design of Bayesian adaptive trials	Dr. Haolun Shi
14:30 - 15:15	Adaptive Trial Designs for Public and Global Health	Dr. Ofir Harari
15:15- 16:00	P-value and Bayesian analysis in randomized-controlled trials in child health research published in 2007 and 2017: a methodological review	Dr. Alex Aregbesola

DAY 1: SEPTEMBER 28

16:00 - 16:15	**Networking and Break**	
16:15 - 17:15	**Trainee Lightning Presentations**	
16:15 - 16:30	Evaluating Platform Designs for Clinical Trials in Patients with Mild Cognitive Impairment	Qirui (Dylan) Hou, University of Toronto
16:30 - 16:45	This is our chance to get results fast": Moral experiences of clinician-investigators and staff involved in adaptive trials during the first wave of the COVID pandemic	Rachel Yantzi, McMaster University
16:45 - 17:00	Identifying Patient Subgroups with Treatment Effect Heterogeneity in Adaptive Platform Trials	Xianglin Zhao, McGill University
17:00 - 17:15	Enhancing the Efficiency of Adaptive Platform Trials Through the Exploration of Alternative Treatment Ranking Methods	Abigail McGrory, University of Toronto
18:00	**Dinner**	

Join the event online

Zoom link for Sept 28-29:
https://us06web.zoom.us/j/9545217464

Meeting ID: 954 521 7464

DAY 2: SEPTEMBER 29

Time	Topic	Speaker(s)
8:30 - 9:30	Discussion of the ethical considerations in adaptive platform trial design and analysis	Dr. Ross Upshur
9:30 - 10:15	Overcoming practical challenges in adaptive platform trials	Dr. Ly-Mee Yu
10:15 - 10:30	**Break**	
10:30 - 11:15	Implementing Good Participatory Practices (GPP) in Adaptive Platform Trials: Ethical and practical challenges	Dr. Lisa Schwartz
11:15 - 12:00	Mastering grant writing and protocol development for Adaptive Platform Trials: strategies, best practices, and insights for success	Dr. Andrew Pinto
12:00 - 12:15	Closing remarks	Dr. Andrew Pinto
12:15 - 13:00	**Lunch**	
13:00 - 17:00	CanTreatCOVID meeting	CanTreatCOVID Team

CanTreatCOVID
Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings

CanTreatCOVID is publicly-funded research evaluating the effectiveness of COVID-19 medications to help people feel better faster, reduce hospitalizations and prevent long COVID.

CanTreatCOVID.org

info@CanTreatCOVID.org

Sessions & Speakers

Angela Cheung, MD PhD FRCPC, is a Professor of Medicine and KY and Betty Ho Chair in Integrative Medicine at University of Toronto and Senior Scientist at University Health Network. Dr. Cheung is part of the Chief Science Advisor Task Force on Post COVID-19 Condition. She is the co-lead of CANCOV (Canadian COVID-19 Prospective Cohort Study) and RECLAIM (Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine) Trial.

Session: Introduction to adaptive platform trials and their advantages over traditional randomized controlled trials

Goals: Understand the basics of adaptive platform trials and their advantages over traditional randomized controlled trials

John Marshall, MD FRCSC FACS FCAHS, is the Canadian lead investigator in the REMAP-CAP trial, co-chair of the WHO Working Group on the Clinical Care and Management of COVID-19, and the chair of the International Forum for Acute Care Trialists. Dr. Marshall is a Professor of Surgery at the University of Toronto and co-investigator for CanTreatCOVID.

Session: Case studies of adaptive platform trials with complex designs

Goals: Learn about complex adaptive platform trials and their designs - 1 simple and elegant APT study involving response-adaptive randomization (REMAP-Cap)

Sessions & Speakers

Jamie Forrest, PhD MPH, is a founding partner of Platform Life Sciences, a clinical research company headquartered in Vancouver and the former Executive Director of The TOGETHER Platform Adaptive Clinical Trial. Dr. Forrest has a PhD in Population and Public Health from the University of British Columbia and a Master of Public Health from Simon Fraser University.

Session: Case studies of adaptive platform trials with complex designs

Goals: Learn about complex adaptive platform trials and their designs - 1 simple and elegant study involving adaptive intervention arms (TOGETHER)

Rubeshan Perumal, MBChB MPH MMed MPhil FCP(SA) Cert Pulmonology (SA) PhD, is a pulmonologist and senior scientist at the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and the University of KwaZulu-Natal, where he leads portfolios in tuberculosis, HIV, and COVID-19 research. His post-doctoral training focused on translational TB research and MDR-TB clinical trials.

Session: Case studies of adaptive platform trials with complex designs

Goals: Learn about complex adaptive platform trials and their designs – 1 large study that adopted a traditional RCT design, but which would have benefited from an adaptive platform trial design

Sessions & Speakers

Anna Heath, PhD MMath, is a Scientist in the Child Health and Evaluative Sciences Program at SickKids Research Institute and an Assistant Professor in the Division of Biostatistics, University of Toronto. Dr. Heath's research focuses on developing innovative statistical methods to design, prioritize and analyze clinical research within a Bayesian framework.

Session: Bayesian analysis in adaptive trials: sample size calculation, simulation, and sequential hypothesis testing

Goals: Learn practical techniques for conducting simulation studies for sample size estimation, and gain understanding of Bayesian methods and sequential hypothesis testing in the context of adaptive platform trials

Haolun Shi, PhD, is an Assistant Professor in the Department of Statistics and Actuarial Science at Simon Fraser University. Dr. Shi served as a CANSSI postdoctoral fellow at Simon Fraser University. His research interests include Bayesian modelling, clinical trial design, functional data analysis, and statistics in sports.

Session: Hands-on practice session for statistical design of Bayesian adaptive trials

Goals: Learn about the statistical considerations in design of Bayesian adaptive trials and performing simulation studies required for the design. Attendees will have access to worked out examples presented using R.

Sessions & Speakers

Ofir Harari, PhD, is the Statistical Lead at Core Clinical Sciences in Vancouver, BC, having previously been a senior Research Principal, Statistics in the Real World and Advanced Analytics division at Cytel Inc. Prior to that, Dr. Harari was a postdoctoral fellow at the University of Toronto and Simon Fraser University. He earned his PhD at Tel Aviv University.

Session: Exploring Bayesian stopping rules through case studies

Goals: Learn about the significance of Bayesian stopping rules in adaptive trials through case studies: 1) a multi-arm, multi-stage adaptive trial design with individually RCT; 2) an adaptive cluster RCT

Alex Aregbesola, MD PhD, is an Assistant Professor in the Department of Pediatrics and Child Health at the University of Manitoba. Dr. Aregbesola completed two post-doctoral fellowships and is involved in clinical trials looking at the methodological approaches in conducting randomized-controlled trials in children.

Session: P-value and Bayesian analysis in randomized-controlled trials in child health research published in 2007 and 2017: a methodological review

Goals: To examine whether Bayesian methodology offers a more reliable alternative to traditional frequentist methods in conducting child health research trials, and to investigate if there's a significant clustering around P-values in randomized controlled trials (RCTs) within this field

Sessions & Speakers

Ross Upshur, MD MA MSc MCFP FRCPC FCAHS, is the Dalla Lana Chair in Clinical Public Health, Professor and Head of the Division of Clinical Public Health at the Dalla Lana School of Public Health and Professor in the Department of Family and Community Medicine in the Temerty Faculty of Medicine, University of Toronto. He is a Senior Scientist in the Lunenfeld Tanenbaum Research Institute and Staff Physician at the Hennick Bridgepoint Hospital at Sinai Health.

Session: Discussion of the ethical considerations in adaptive platform trial design and analysis

Goals: To discuss ethical challenges in adaptive platform trial design and analysis and explore solutions

Ly-Mee Yu, DPhil MSc, is a Professor of Clinical Trials and Biostatistics at the Nuffield Department of Primary Care Health Sciences at the University of Oxford. She has over 27 years of experience as a medical statistician, specifically in clinical trials for the past 15 years, and has worked in a wide range of clinical areas.

Session: Overcoming practical challenges in adaptive platform trials

Goals: Discuss practical challenges in adaptive platform trials and how to overcome them

Sessions & Speakers

Lisa Schwartz, PhD, is the Arnold L. Johnson Chair in Health Care Ethics, a co-lead on a program of research on humanitarian health ethics, and a Professor in the Department of Health Research Methods, Evidence & Impact at McMaster University. Dr. Schwartz's research background is in ethics and human research, evaluation of ethics education in medicine, and advocacy in health care.

Session: Implementing Good Participatory Practices (GPP) in Adaptive Platform Trials: Ethical and practical challenges

Goals: To present reflections on ethical and practical challenges of implementing GPP-EP for adaptive platform trials from experience during COVID-19

Andrew Pinto, MD CCFP FRCPC MSc, is the founder and director of Upstream Lab. He holds the CIHR Applied Public Health Chair in Upstream Prevention and is the Principal Investigator of CanTreatCOVID. Dr. Pinto is a Public Health and Preventive Medicine specialist and family physician at St. Michael's Hospital in Toronto and an Associate Professor at the University of Toronto.

Session: Mastering Grant Writing and Protocol Development for Adaptive Platform Trials: Strategies, Best Practices, and Insights for Success

Goals: Learn about grant writing and protocol development for adaptive platform trials

Share your feedback

Your feedback will help us improve our future events. Please scan the QR codes below to complete the surveys.

APT Scientific Meeting

Sessions on Day 1

Sessions on Day 2

Our Location

CHESTNUT
CONFERENCE CENTRE
89 Chestnut Street
Toronto, ON
M5G 1R1



GETTING HERE

From Union Station
Take the train northbound to St. Patrick Station or Dundas Station.

From St. Patrick Station
Walking east on Dundas Street, Chestnut is at the 1st set of lights east of University Avenue.
Time: 2 to 5-minute walk

From Dundas Station
Walking west on Dundas Street, Chestnut Street is at the 2nd set of lights west of Yonge Street.
Time: 5 to 7-minute walk

From Town Inn Suites
Head north on Church St towards Charles St E. Enter the Bloor-Yonge station via Hayden Street. Take the southbound train to Dundas Station.

From the Airport
Airport taxis and rideshares are available at the terminals. Travel time is approximately 45 minutes.

Notes

Notes

Scientific Committee

Dr. Andrew Pinto
Upstream Lab
University of Toronto

Dr. Benita Hosseini
Upstream Lab
University of Toronto

Dr. Angela Cheung
CAN TAP TALENT
University of Toronto

Dr. Alan Katz
Manitoba Centre for Health Policy
University of Manitoba

Dr. Rubeshan Perumal
Centre for the AIDS Programme of Research in South Africa (CAPRISA)

Sponsors

UPSTREAMLAB

UNIVERSITY OF TORONTO

Canadian Primary Care Trials Network | Réseau canadien d'essais en soins primaires

CAN TAP TALENT

UNIVERSITY OF OXFORD

CAPRISA
CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA

CIHR IRSC | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada

Santé Canada | Health Canada

Public Health Agency of Canada
Agence de la santé publique du Canada